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Introduction production of GnRH release by the 
6Since its  descript ion by American hypothalamus. 
gynaecologists, Irving Stein and Michael 
 1 ,  2
Leventhal in 1935 , considerable An autosomal dominant transmission with 
information has accumulated about the incomplete penetrance has been shown 
pathology, pathogenesis and manifestations with differential inheritance of the various 
7, 8of the Polycystic Ovary Syndrome (PCOS). It aspects of the syndrome  Furthermore, a 
has also been described as polycystic ovary sub-clinical PCOS may exist which may then 
 9d i s e a s e ,  f u n c t i o n a l  o v a r i a n  become expressed over time. 
hyperandrogenism, hyperandrogenic 
chronic anovulation, ovarian dysmetabolic Pathophysiology  
syndrome and ovarian androgen excess .This Basically a disturbance in the hypothalamic-
probably highlights a lack of unanimity in pituitary-ovarian axis hormonal regulatory 
nomenclature.  Recent advances in pathway is triggered by abnormal adrenal 
understanding of its pathophysiology and androgen production. The result is elevated 
pathogenesis have unfolded a number of LH and normal or low FSH. There is also 
long term health risks to the syndrome. This increased levels of estrogens primarily 
enables specific treatment or prevention by oestrone and oestradiol. These results in 
way of screening for these risks in patients suppression of pituitary FSH secretion and 
3 , 4with the syndrome . PCOS is the increase release of LH. This results in 
commonest endocrine abnormality in increased product ion of  androgen 
gynaecological practice affecting 5-20% of precursors by ovarian theca cells. The 
4, 5
women of reproductive age  of all races and peripheral conversion of androgens to 
nationalities. oestrogens primarily oestrogens strengthen 
the feedback effect on the pituitary gland.
Aetiology
Debate continues as to the exact cause of 
PCOS. A widely accepted hypothesis 
proposes androgen overproduction by the 
adrenal gland at puberty or at times of stress 
resulting in disturbance in the cyclical 
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Abstract
 
Since its description by American gynaecologists, Irving Stein and Michael Leventhal in 1935,  
considerable information has accumulated about the pathology, pathogenesis and 
manifestations of what is currently known as polycystic ovary disease. Although there is a lack 
of unanimity in nomenclature, this condition continues to afflict women, usually manifesting 
with menstrual disturbances and infertility. Recent advances in understanding of its 
pathophysiology and pathogenesis have unfolded a number of long term health risks to the 
syndrome. This makes specific treatment or prevention by way of screening for these risks an 
imperative in patients with the syndrome.
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High serum androgens inhibit  the may be due to the hormonal imbalance or by 
production of sex hormone binding globulin self-esteem problems often experienced by 
in the liver indirectly increasing the levels of these women. A number of patients are 
free estrogens in the blood. Elevated identified only when they present with 
 10androgen levels in the ovary exerts inhibitory unrelated symptoms.
effect in the follicular maturation, this in 
conjunction with the continuous but Diagnosis is made by TVS or TAS in a patient 
diminished FSH levels encourage growth of with clinical and biochemical features of 
follicles but not their maturation thus the PCOS. The ovaries are generally enlarged 1.5 
finding of numerous small sized follicles in to 3 times the normal size with thickened 
various phases of development and atresia. smooth, pearl-white outer surface. The 
stroma is echogenic and small peripherally 
Obesity may play a pathogenic role in the arranged follicles give it a string of pearl 
development of the syndrome in susceptible appearance. There are no dominant follicles. 
7i n d i v i d u a l s  . I t  a l s o  wo rs e n s  t h e  However about 30% of patients with 
symptomatology and endocrine profile as endorinological findings of PCOS have 
11well as contributing to insulin resistance and normal sized ovaries on sonograms . 
associated hyperinsulinemia thereby Doppler analysis can be a valuable additional 
increasing the risk of type 2 diabetes. tool for the diagnosis of polycystic ovary 
syndrome.   Studies have shown significantly 
Presentation elevated uterine artery pulsatility index 
PCOS can be diagnosed at any age from values associated with a typical low 
menarche to the menopause but typically res istance  index  of  st roma ovary  
presents in patients in their late teens or vascularization. The plasticity index show 
early twenties with acne, hirsutism or positive correlation with the Luteinizing 
difficulty to conceive respectively. Although hormone/follicle-stimulating hormone 
uncommon, patients could present with ratio, and the resistance index show negative 
primary amenorrhoea between the ages of correlation. The elevated uterine artery 
 3
10 and 20 years due to PCOS . r e s i s t a n c e  a r e  c o r r e l a t e d  w i t h  
12
androstenedione levels.
Patients are obese in a third of cases with 
o l igomenorrhoea and amenorrhea   Magnetic Resonance Imaging [MRI] is useful 
typically punctuated by occasional heavy as an adjunct. It is more sensitive than 
bleeding due to absence of progesterone. sonography, its findings however is less 
Infertility due to chronic anovulation and specific. It is expensive and not available in 
features of androgen excess including male every unit.
pattern baldness androgenic alopecia) acne, Biochemical features of PCOS include 
oily skin, seborrhoea,  acanthosis nigricans elevated LH with normal or low FSH. LH: FSH 
(dark patches of skin tan to dark brown), of two or more is common. Elevated 
acrochordons (skin tags) which are tiny flaps androgens androstenedione, low sex 
of skin over areas of the skin being rubbed by hormone binding globulin, high oestradiol, 
clothes like behind the neck, under the arm , oestrone and elevated serum prolactin are 
and under the breast. associated features.  There is associated 
insulin resistance i.e. high fasting insulin 
Other features include PMS-like symptoms w i t h  n o r m a l  o r  h y p o g l y c a e m i a .  
(bloating, mood swings pelvic pain, Dyslipideamia, raised triglycerides and total 
backaches) Depressions and anxiety which and low density lipoprotein, cholesterol are 
additional biochemical features. is associated with long term health 
13, 14  
consequences . Insulin resistance has 
PCOS is an important metabolic disease and been linked to later development of  
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Table 1
The Spectrum of clinical manifestation of Polycystic Ovary Syndrome
impaired glucose tolerance (IGT) and type 11 infertility, chronic estrogen exposure, 
diabetes. Evidence from long-term cohort obesity and diabetes mellitus. It has been 
studies and case series points to a 10-20% demonstrated in numerous studies that 
risk of diabetes which usually sets in at women who have not achieved a pregnancy 
15, 16. have two to three times the risk of around the middle age  Beta cell 
developing endometrial cancer compared to dysfunction and hyperinsulinemia have 
19been found in both lean and obese patients women who have .
 16alike.  Women with PCOS experience severe 
PCOS is also associated with increased risk of oligomenorrhoea and amenorrhoea in the 
c a rd i o v a s c u l a r  d i s e a s e  i n c l u d i n g  presence of premenopausal levels of 
atherosclerotic condition and myocardial oestrogens. Anovulatory cycles result in 
12, 17, 18.infarction Obesity hypertension, chronic exposure of the endometrial lining 
hyperandrogenism further increase the risk to estrogen with out progestogenic 
of cardiovascular disease. This is frequently protection. This results in an increased risk of 
associated with abnormal lipid profile in developing endometrial hyperplasia and 
form of raised triglycerides and total and low endometrial cancer before the age of 45 
16, 17, 18
20, 21density lipoprotein cholesterol . years . The lesions tend to be well-
differentiated cancers, suggesting the 
21The risk of endometrial cancer in PCOS is influence of estrogen exposure
caused by a coupling of the effects of 




































































27who are 21 to 50 pounds (9.5-22.7 kg) problems in obese women with PCOS 
overweight have a three fold increase in the 
risk of endometrial cancer. Women who Management of PCOS 
weigh more than 50 pounds over their The heterogeneity of the syndrome makes it 
recommended weight have a 10 fold necessary to individualise treatment. Obese 
22
increase in risk . This is due the an increased patients should have fasting blood sugar and 
peripheral conversion of androstenedione to urinalysis and abnormal results investigated 
estrone in adipose tissue resulting in chronic with a 75g OGTT because of the high 
exposure of the endometrium to increased incidence of type II Diabetes. Measurement 
circulating estrogen, thus increasing the risk of fasting cholesterol, lipids and triglycerides 
of endometrial cancer. if abnormal, will require further surveillance 
or treatment with cholesterol lowering Diabetes mellitus  increases a woman's risk 
agents.of developing endometrial cancer by greater 
23than two fold .The effect may be mediated 
Obesitythrough elevated oestrogen levels in diabetic 
Weight loss should be encouraged through women, hyperinsulinemia or insulin-like 
diet and exercise. Studies have shown growth factor-I (IGF-I). The association 
weight loss to improve both the endocrine between diabetes and risk of endometrial 
and metabolic profile as well as the cancer was considered in a large case-control 
likelihood of spontaneous ovulation and a study involving 752 women conducted in 
 28healthy pregnancy . Others have shown Italy which results confirm that non-insulin-
reduction of ovarian volume and micro dependent diabetes increases the risk of 
24 fol l ic les with improvement in the endometrial cancer 
29
anthropometric indices . The 'correct' diet is The associated increased risk of breast cancer  in 
one that is acceptable to the individual but PCOS is however disputed by the result of a large 
 diets low in carbohydrates and fats are prospective cohort study  which showed  no 
sensible. A target BMI of around 27kg/m is significant increase in the risk of breast cancer in 
2
ideal  and the help of a dietician may be association with PCOS compared with controls 
 25 invaluable. The role of anti-obesity drugs (RR 1.2  95% CI 0.7-2.0)
such as orlistat and sibutramine is 
inconclusive although some early reports PCOS and Pregnancy 
 
show effective weight loss with.  Their use Not only are patients sub fertile due to 
should however be monitored as there are chronic an ovulation, the high levels of 
no long term studies on their safety.Luteinizing hormone (LH) predisposes them 
Exercise is a useful adjunct in improving end-to recurrent miscarriages. Prepregnancy 
organ sensitivity to insulin and should be suppression of LH however neither reduces 
encouraged. Modifying lifestyle factors the risk of miscarriage nor improves the live 
26. including alcohol and tobacco consumption birth rate It is therefore not an appropriate 
and psychosocial stressors are useful in the treatment option for PCOS patients with 
long term management.recurrent miscarriage.
Ovulation induction in patients with PCOS is 
Use of Insulin Sensitizing Agents (ISA)associated with increased risk of ovarian 
The recent understanding of the long term hyper stimulation syndrome (OHSS) and 
co n s e q u e n c es  o f  P CO S  h as  b e e n  multiple pregnancies due to their increased 
accompanied by renewed interest in the use sensitivity to ovulation inducing agents. 
of pharmacological agents such as Gestational diabetes and abnormal glucose 
metformin and triglitazone in order to tolerance in pregnancy are common medical 
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reduce insulin resistance, risk of diabetes Ovulation induction often requires careful 
and hyperandrogenism. progression through various treatment 
options to reduce the risk of multiple 
Metformin is preferred to triglitazone due to pregnancy and OHSS. Anti-oestrogens such 
the latter's adverse effect on hepatic as clomiphene citrate (50-100mg) or 
function. Metformin is a biguanide which tamoxifen (20-40mg) are commonly used. 
reduces insulin resistance by inhibiting the Patients with PCOS generally do well with 
hepatic glucose production and increasing anti- oestrogens due to their high oestrogen 
peripheral tissue sensitivity to insulin. It is levels. 
safe and effective and its benefits include 
improving obesity, hyperandrogenism, Clomiphene citrate achieves a 60-80% 
fertility, insulin sensitivity as well as lipid ovulation rate but the pregnancy rate is only 
profile. It may have a direct effect on ovarian about 40%. Clomiphene acts at the level of 
30, 31 the hypothalamus, pituitary and ovary. It is function .  It is especially indicated in 
started at a dose of 50mg for five days of obese patients with PCOS. Started at a dose 
spontaneous menstruation or progesterone 750mg twice daily, it has no specific licence 
induced bleed, when ovulation occurs at this for this use and patients hepatic and renal 
dosage there is no advantage to increasing functions must be assured before 
the dose in subsequent cycles. Otherwise, a commencing therapy. Side effects include 
second course of 100mg (in single dose) for anorexia, nausea flatulence and diarrhoea. 
five days should be given. Increase in dose This may be reduced by taking metformin 
beyond 100mg rarely confers any benefit just before food and gradually increasing the 
and can be associated with thickening of dose from 750mg at night to 750mg twice 
cervical mucus and a negative effect on the daily after one week. The dose may need to 
endometrium with consequent decrease in be titrated to individual need. 
fertility rate. Women on clomiphene citrate 
should be monitored with ultrasound, to Metformin does not cause lactic acidosis in 
tract ovulation and also reduce the 10% risk non-diabetic women with normal hepatic 
of multiple pregnancy.  Majority of patients and renal functions. It is usually discontinued 
will ovulate after three courses. Once in pregnancy though it has no teratogenic 
ovulatory dose has been reached the effect. . Most women require 4-6 months of 
cumulative pregnancy rate continues to metformin therapy before achieving 
increase up to ten to twelve cycles ovulatory menses. 
36It could be used long term although its .However use of the drug should be limited 
benefits in reducing the incidence of IGT, to six cycles only. This is because its safety 
type II diabetes and dyslipideamia are  yet to beyond s ix  months has  not  been 
be proven by RCTs.It has however been demonstrated.
 proven to be effective and early reports 
indicate that it may reduce the risk of There have been reports of ovarian cancer 
32,33,34 associated with use of fertility drugs gestational diabetes . It interacts with 
however infertility itself is a primary risk iodine and must be discontinued for three 
 37days after use of iodine containing contrast factor.  Epidemiological data however does 
medium. Newer ISA like Rosiglitazone, suggest that the prolonged use of clomid 
proglitazone are currently being evaluated. may increase the risk of ovarian cancer 
D-chiro-inositol, a phosphoglycan has also which emphasizes the need for caution. 
35 Tamoxifen is useful in selected patients but been effective in patients with PCOS .
its effects on endometrium make it a second Use of Ovulation Induction Agents 
7675
line drug. gonadotropin further stimulates the ovaries. 
Moderate to severe conditions are treated in 
Clomiphene Resistance hospital with intravenous fluids and heparin 
Twenty percent of patients are resistant to t o  p r e v e n t  d e h y d r a t i o n  a n d  
Clomiphene citrate for which a number of thromboembolism. Although rare, OHSS is 
other agents are used alone or in potentially fatal and must be prevented by 
combination. Metformin in addition to appropriate monitoring of gonadotropin 
clomiphene citrate is more effective than therapy.
Clomiphene alone. This is supported by 
evidence from meta-analysis of 15 RCT  The advent of transvaginal ultrasonography 
involving over 500 women which  showed has enabled multiple pregnancies to be 
 that metformin is effective in achieving reduced to approximately 7% because of its 
ovulation in women with polycystic ovary higher resolution and clearer view of the 
 syndrome, with odds ratios of 3.88 (95% developing follicles. The cumulative 
 
confidence interval 2.25 to 6.69) for conception and live birth rate after 6 months 
metformin compared with placebo and 4.41 is about 62% and 54% respectively and after 
  39 (2.37 to 8.22) for metformin and clomiphene 12 months 73 and 62% respectively. It is 
 compared with clomiphene alone. An reasonable to suspend treatment if three or 
analysis of pregnancy rates shows a more follicles develop in order to reduce risk 
 significant treatment effect for metformin of multiple pregnancy.
and clomiphene (Odds ratio 4.40, 1.96 to GnRH though effective is expensive, stressful 
389.85) . This evidence supports the addition and time consuming requiring intensive 
of metformin to clomiphene resistant monitoring.
patients
Laparoscopic Ovarian Diathermy (LOD)
Gonadotropins in form of dose FSH, LOD is now the surgical option of choice, 
recombinant FSH, or urinary FSH are avoiding peritubal adhesions and follicular 
reasonable efficient strategy for inducing wastage of wedge ovarian resection, (WOR). 
ovulation in clomiphene resistant patients. It is also minimally invasive and has a high 
The use of gonadotropins must be closely success rate in achieving unifollicular 
monitored with ultrasound scan and serum ovulation and singleton pregnancy with 
oestradiol levels to minimise risk of OHSS comparative eff icacy to parenteral  
 34and higher multiple pregnancy. gonadotropins. .  There is no risk of OHSS or 
OHSS occurs if too many follicles are problems with high order multiple 
stimulated (>10mm) and presents with pregnancy. It is especially suitable for 
abdominal distension, nausea, vomiting and patients in who USS monitoring is not 
sometimes difficulty in breathing. The available.
mechanism of OHSS may be activation of 
ovarian renin  angiotension pathway and There is currently an uncertainty about the 
excessive stimulation of vascular epidermal optimum number of punctures to be applied 
growth factor (VEGF). Ascites, pleural and at LOD and the amount of energy to use. 
pericardial effusion aggravate this already Retrospective analysis has however shown 
serious condition and the resultant that more than 2 punctures per ovary are 
haemoconcentration could result in required to achieve an effect. Application of 
thromboembolism. The condition worsens if seven or more punctures results in excessive 
pregnancy has resulted from the treatment destruct ion of  the  ovary  without  
as the placental  human chorionic  improvement of results and should be 
Trop J Obstet Gynaecol, 25 (2), October 2008.                                                                                         ISSN 0189 5178 Trop J Obstet Gynaecol, 25 (2), October 2008.                                                                                         ISSN 0189 5178
 35  39avoided. .  effects and inconveniences. . They however 
The procedure can be done as an outpatient are useful pending the effect of drug therapy.
and has less risks of trauma and fewer Drug therapies take at least six to nine 
postoperative adhesions compared to WOR. months to be effective because of the length 
Repeat LOD has been shown to be effective of the hair cycle. The best pharmacological 
in some selected patients. method of proven effectiveness is a 
Regarding technique, similar results have combination of the synthetic progesterone 
been obtained using biopsy, cauterisation cyproterone acetate (CPA 50mg-100mg) and 
micro coagulation or laser therapy which is > ethinyl oestradiol 35 mcg. The cyproterone is 
50% ovulation and a mean pregnancy rate of used for the first 10 days of the cycle the 
50%. Use of transvaginal hydro laparoscopic “reversed sequential” method while the 
ovarian drilling has been shown to be an oestrogen for the first 21 days .After a gap of 
effective alternative option with equivalent 7days during which menstruation occurs, 
ovulation and pregnancy rate and avoids the the regime is repeated again. Dianette is 
  36 combination of CPA and Ethinyl oestradiol inherent risks of laparoscopy. The risks of 
(CPA/EE 2mg/35mcg). Though in a lower LOD include premature ovarian failure and 
dose, is convenient, easier to use and equally ovarian atrophy. 
effective. Cyproterone can rarely cause liver 
damage therefore liver function test should IVF and PCOS
be checked every six months.A proportion of patients will ultimately 
T h i r d  g e n e r a t i o n  c o m b i n e d  o r a l  require some form of assisted reproduction 
contraceptives are very useful in control of but caution must be exercised during super 
acne and hirsutism. Yasmin, the new ovulation because of higher risk of OHSS.  
drosperinone containing contraceptive has These patients have a higher average 
shown promise.number of oocytes per stimulation than 
Spironolactone has an anti androgenic effect controls but because of the higher rate of 
and may be used in a dose of 25-100mg in immature oocytes, they  tend to have a 
women in who the combined oral slightly lower rate of fertilisation than 
 38 contraceptive pills are contraindicated. control (52 vs. 61%)..  However both IVF and 
Anti- androgens like finesteride, flutamide ICSI are  efficient for PCOS patients.
and ketoconazole are also effective    but   Management of Acne and Hirsutism
must be used with effective contraception as Acne and excessive body hair growth in a 
they interfere with genital development of a male pattern distribution are cutaneous 
 40male foetus. .responses to excessive androgen stimulation 
and may be the main concern of especially 
In conclusion PCOS is a heterogeneous young  women at  presentat ion.  A  
disorder with associated long term standardised scoring system such as the 
metabolic risks and endometrial cancer. Ferriman and Galloway score should be used 
Treatment is individualised according to to evaluate the degree of hirsutism before 
patient needs. Effective surveillance could and during treatment.
prevent or enable early diagnosis of 
dyslipideamia and type 2 diabetes while Treatment depends on severity and can be 
endometrial protection with progesterone either local or systemic. Physical methods 
will reduce the risk of cancerus ing  shav ing ,  wax ing ,  b leaching ,  
e l e c t ro l y s i s  o r  i n d e e d  l a s e r  a n d  
photothermolysis achieve quick but 
temporary relief. Each has its unique side 
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